PTGX logo

Protagonist Therapeutics, Inc. (PTGX) EBIT

annual EBIT:

$252.84M+$346.50M(+369.98%)
December 31, 2024

Summary

  • As of today (September 16, 2025), PTGX annual earnings before interest & taxes is $252.84 million, with the most recent change of +$346.50 million (+369.98%) on December 31, 2024.
  • During the last 3 years, PTGX annual EBIT has risen by +$378.69 million (+300.92%).
  • PTGX annual EBIT is now at all-time high.

Performance

PTGX EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherPTGXincome statement metrics

quarterly EBIT:

-$42.04M-$22.73M(-117.72%)
June 30, 2025

Summary

  • As of today (September 16, 2025), PTGX quarterly earnings before interest & taxes is -$42.04 million, with the most recent change of -$22.73 million (-117.72%) on June 30, 2025.
  • Over the past year, PTGX quarterly EBIT has dropped by -$3.25 million (-8.37%).
  • PTGX quarterly EBIT is now -120.38% below its all-time high of $206.31 million, reached on March 31, 2024.

Performance

PTGX quarterly EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherPTGXincome statement metrics

TTM EBIT:

$23.98M-$3.25M(-11.93%)
June 30, 2025

Summary

  • As of today (September 16, 2025), PTGX TTM earnings before interest & taxes is $23.98 million, with the most recent change of -$3.25 million (-11.93%) on June 30, 2025.
  • Over the past year, PTGX TTM EBIT has dropped by -$128.26 million (-84.25%).
  • PTGX TTM EBIT is now -90.52% below its all-time high of $252.84 million, reached on December 31, 2024.

Performance

PTGX TTM EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherPTGXincome statement metrics

EBIT Formula

EBIT = Revenue − COGS − Operating Expenses

PTGX EBIT Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+370.0%-8.4%-84.3%
3 y3 years+300.9%-1.4%+118.0%
5 y5 years+425.4%-132.5%+133.9%

PTGX EBIT Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+292.5%-120.4%+0.7%-90.5%+115.7%
5 y5-yearat high+292.5%-120.4%+0.7%-90.5%+115.7%
alltimeall timeat high+292.5%-120.4%+0.7%-90.5%+115.7%

PTGX EBIT History

DateAnnualQuarterlyTTM
Jun 2025
-
-$42.04M(+117.7%)
$23.98M(-11.9%)
Mar 2025
-
-$19.31M(-115.2%)
$27.22M(-89.2%)
Dec 2024
$252.84M(-370.0%)
$126.78M(-405.8%)
$252.84M(+69.6%)
Sep 2024
-
-$41.45M(+6.9%)
$149.11M(-2.1%)
Jun 2024
-
-$38.79M(-118.8%)
$152.24M(+2.4%)
Mar 2024
-
$206.31M(+795.1%)
$148.68M(-258.8%)
Dec 2023
-$93.65M(-28.7%)
$23.05M(-160.1%)
-$93.65M(-38.9%)
Sep 2023
-
-$38.33M(-9.5%)
-$153.22M(+4.1%)
Jun 2023
-
-$42.35M(+17.6%)
-$147.19M(+0.6%)
Mar 2023
-
-$36.02M(-1.4%)
-$146.28M(+11.3%)
Dec 2022
-$131.37M(+4.4%)
-$36.52M(+13.0%)
-$131.37M(-0.4%)
Sep 2022
-
-$32.30M(-22.1%)
-$131.87M(-1.2%)
Jun 2022
-
-$41.44M(+96.3%)
-$133.50M(+8.6%)
Mar 2022
-
-$21.11M(-43.0%)
-$122.94M(-2.3%)
Dec 2021
-$125.84M(+95.9%)
-$37.02M(+9.1%)
-$125.84M(+17.0%)
Sep 2021
-
-$33.93M(+9.9%)
-$107.59M(+32.2%)
Jun 2021
-
-$30.88M(+28.6%)
-$81.41M(+18.7%)
Mar 2021
-
-$24.02M(+28.1%)
-$68.61M(+6.8%)
Dec 2020
-$64.25M
-$18.76M(+142.2%)
-$64.25M(+3.7%)
Sep 2020
-
-$7.74M(-57.2%)
-$61.96M(-12.4%)
DateAnnualQuarterlyTTM
Jun 2020
-
-$18.08M(-8.0%)
-$70.73M(-15.2%)
Mar 2020
-
-$19.66M(+19.3%)
-$83.45M(+7.4%)
Dec 2019
-$77.71M(+95.6%)
-$16.48M(-0.2%)
-$77.71M(+4.9%)
Sep 2019
-
-$16.51M(-46.4%)
-$74.10M(+10.6%)
Jun 2019
-
-$30.80M(+121.3%)
-$66.98M(+47.5%)
Mar 2019
-
-$13.92M(+8.2%)
-$45.41M(+14.3%)
Dec 2018
-$39.72M(+7.5%)
-$12.87M(+37.0%)
-$39.72M(+35.0%)
Sep 2018
-
-$9.39M(+1.6%)
-$29.43M(+17.6%)
Jun 2018
-
-$9.24M(+12.3%)
-$25.02M(-19.1%)
Mar 2018
-
-$8.23M(+219.8%)
-$30.91M(-16.4%)
Dec 2017
-$36.96M(+13.1%)
-$2.57M(-48.3%)
-$36.96M(-19.3%)
Sep 2017
-
-$4.98M(-67.1%)
-$45.78M(-4.5%)
Jun 2017
-
-$15.13M(+6.0%)
-$47.94M(+20.2%)
Mar 2017
-
-$14.27M(+25.2%)
-$39.90M(+22.1%)
Dec 2016
-$32.67M(+120.8%)
-$11.40M(+59.7%)
-$32.67M(+24.3%)
Sep 2016
-
-$7.14M(+0.7%)
-$26.27M(+37.3%)
Jun 2016
-
-$7.09M(+0.7%)
-$19.13M(+58.9%)
Mar 2016
-
-$7.04M(+40.8%)
-$12.04M(+56.6%)
Dec 2015
-$14.79M(+58.8%)
-$5.00M(+86.0%)
-$7.69M(+186.0%)
Mar 2015
-
-$2.69M
-$2.69M
Dec 2014
-$9.32M
-
-

FAQ

  • What is Protagonist Therapeutics, Inc. annual earnings before interest & taxes?
  • What is the all time high annual EBIT for Protagonist Therapeutics, Inc.?
  • What is Protagonist Therapeutics, Inc. annual EBIT year-on-year change?
  • What is Protagonist Therapeutics, Inc. quarterly earnings before interest & taxes?
  • What is the all time high quarterly EBIT for Protagonist Therapeutics, Inc.?
  • What is Protagonist Therapeutics, Inc. quarterly EBIT year-on-year change?
  • What is Protagonist Therapeutics, Inc. TTM earnings before interest & taxes?
  • What is the all time high TTM EBIT for Protagonist Therapeutics, Inc.?
  • What is Protagonist Therapeutics, Inc. TTM EBIT year-on-year change?

What is Protagonist Therapeutics, Inc. annual earnings before interest & taxes?

The current annual EBIT of PTGX is $252.84M

What is the all time high annual EBIT for Protagonist Therapeutics, Inc.?

Protagonist Therapeutics, Inc. all-time high annual earnings before interest & taxes is $252.84M

What is Protagonist Therapeutics, Inc. annual EBIT year-on-year change?

Over the past year, PTGX annual earnings before interest & taxes has changed by +$346.50M (+369.98%)

What is Protagonist Therapeutics, Inc. quarterly earnings before interest & taxes?

The current quarterly EBIT of PTGX is -$42.04M

What is the all time high quarterly EBIT for Protagonist Therapeutics, Inc.?

Protagonist Therapeutics, Inc. all-time high quarterly earnings before interest & taxes is $206.31M

What is Protagonist Therapeutics, Inc. quarterly EBIT year-on-year change?

Over the past year, PTGX quarterly earnings before interest & taxes has changed by -$3.25M (-8.37%)

What is Protagonist Therapeutics, Inc. TTM earnings before interest & taxes?

The current TTM EBIT of PTGX is $23.98M

What is the all time high TTM EBIT for Protagonist Therapeutics, Inc.?

Protagonist Therapeutics, Inc. all-time high TTM earnings before interest & taxes is $252.84M

What is Protagonist Therapeutics, Inc. TTM EBIT year-on-year change?

Over the past year, PTGX TTM earnings before interest & taxes has changed by -$128.26M (-84.25%)
On this page